

ABSTRACT

This invention relates to modified IL-4 mutein receptor antagonists comprising an
5 IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and
dosages and methods of administration thereof for therapeutic purposes are also provided.
These modified IL-4 mutein receptor antagonists, compositions and methods provide a
treatment option for those individuals afflicted with a respiratory disorder such as asthma
by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia.
10 More particularly, these antagonists have an increased duration of effect versus
unmodified IL-4RA by virtue of a greater plasma half-life.